Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells

Nanomedicine nowadays offers novel solutions in cancer therapy and diagnosis by introducing multimodal treatments and imaging tools in one single formulation. Nanoparticles acting as nanocarriers change the solubility, biodistribution and efficiency of therapeutic molecules, reducing their side effects. In order to successfully  apply these novel therapeutic approaches, efforts are focused on the biological functionalization of the nanoparticles to improve the selectivity towards cancer cells. In this work, we present the synthesis and characterization of novel multifunctionalized iron oxide magnetic nanoparticles (MNPs) with antiCD44 antibody and gemcitabine derivatives, and their application for the selective treatment of CD44-positive cancer cells. The lymphocyte homing receptor CD44 is overexpressed in a large variety of cancer cells, but also in cancer stem cells (CSCs) and circulating tumor cells (CTCs). Therefore, targeting CD44-overexpressing cells is a challenging and promising anticancer strategy. Firstly, we demonstrate the targeting of antiCD44 functionalized MNPs to different CD44-positive cancer cell lines using a CD44-negative non-tumorigenic cell line as a control, and verify the specificity by ultrastructural characterization and downregulation of CD44 expression. Finally, we show the selective drug delivery potential of the MNPs by the killing of CD44-positive cancer cells using a CD44-negative non-tumorigenic cell line as a control. In conclusion, the proposed multifunctionalized MNPs represent an excellent biocompatible nanoplatform for selective CD44-positive cancer therapy in vitro.

[1]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[2]  Paula T. Hammond,et al.  Bimodal Tumor-Targeting from Microenvironment Responsive Hyaluronan Layer-by-Layer (LbL) Nanoparticles , 2014, ACS nano.

[3]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[4]  J W Hershey,et al.  Methyl 4-mercaptobutyrimidate as a cleavable cross-linking reagent and its application to the Escherichia coli 30S ribosome. , 1973, Biochemistry.

[5]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[6]  R. Ravichandran,et al.  Nanotechnology-Based Drug Delivery Systems , 2009 .

[7]  Valeria Grazú,et al.  Designing novel nano-immunoassays: antibody orientation versus sensitivity , 2010 .

[8]  J. Veciana,et al.  Intracellular targeting of CD44+ cells with self-assembling, protein only nanoparticles. , 2014, International journal of pharmaceutics.

[9]  R. Miranda,et al.  Controlled synthesis of uniform magnetite nanocrystals with high-quality properties for biomedical applications , 2012 .

[10]  Weijun Su,et al.  CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. , 2012, Biomaterials.

[11]  K. Gee,et al.  Recent advances in the regulation of CD44 expression and its role in inflammation and autoimmune diseases. , 2004, Archivum immunologiae et therapiae experimentalis.

[12]  M. Zöller.  CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? , 2011, Nature Reviews Cancer.

[13]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[14]  Harikrishna Nakshatri,et al.  CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis , 2006, Breast Cancer Research.

[15]  M. Robinson,et al.  Clathrin and adaptors. , 1998, Biochimica et biophysica acta.

[16]  M. Mahmoudi,et al.  Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. , 2011, Advanced drug delivery reviews.

[17]  D. F. Barber,et al.  Dimercaptosuccinic acid-coated magnetite nanoparticles for magnetically guided in vivo delivery of interferon gamma for cancer immunotherapy. , 2011, Biomaterials.

[18]  Sunita Yadav,et al.  Multi-functional nanocarriers to overcome tumor drug resistance. , 2008, Cancer treatment reviews.

[19]  Miqin Zhang,et al.  Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. , 2010, Advanced drug delivery reviews.

[20]  Marilena Hadjidemetriou,et al.  In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles. , 2015, ACS nano.

[21]  Rodolfo Miranda,et al.  Engineering Iron Oxide Nanoparticles for Clinical Settings , 2014, Nanobiomedicine.

[22]  A. Roque,et al.  Antibody-conjugated nanoparticles for therapeutic applications. , 2012, Current medicinal chemistry.

[23]  Tim Holland-Letz,et al.  Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay , 2013, Nature Biotechnology.

[24]  P. Herrlich,et al.  CD44: From adhesion molecules to signalling regulators , 2003, Nature Reviews Molecular Cell Biology.

[25]  Joel A Swanson,et al.  Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. , 2003, Advanced drug delivery reviews.

[26]  Eugene Lee,et al.  Highly selective CD44-specific gold nanorods for photothermal ablation of tumorigenic subpopulations generated in MCF7 mammospheres , 2012, Nanotechnology.

[27]  André F. Vieira,et al.  Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype , 2011, Journal of Clinical Pathology.

[28]  S. Rehbein,et al.  Cryo X-ray nano-tomography of vaccinia virus infected cells , 2011, Journal of Structural Biology.

[29]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Aires,et al.  Multifunctionalization of magnetic nanoparticles for controlled drug release: a general approach. , 2014, European journal of medicinal chemistry.

[31]  Martin G Pomper,et al.  State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[32]  K. Krishnan.  Biomedical Nanomagnetics: A Spin Through Possibilities in Imaging, Diagnostics, and Therapy , 2010, IEEE Transactions on Magnetics.

[33]  S. Goodison,et al.  CD44 cell adhesion molecules. , 1999, Molecular pathology : MP.

[34]  C. Serna,et al.  Large scale production of biocompatible magnetite nanocrystals with high saturation magnetization values through green aqueous synthesis. , 2013, Journal of materials chemistry. B.

[35]  S. Asuthkar,et al.  Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer , 2013, Molecular biology of the cell.

[36]  P. Couvreur.  Nanoparticles in drug delivery: past, present and future. , 2013, Advanced drug delivery reviews.

[37]  Chun-you Wang,et al.  Cancer Stem-Like Cells Enriched in Panc-1 Spheres Possess Increased Migration Ability and Resistance to Gemcitabine , 2011, International journal of molecular sciences.

[38]  Ali Khademhosseini,et al.  Biocompatibility of engineered nanoparticles for drug delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[39]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.